Bhargave Chaitanya, Verma Manish, Jakes Rupert W, Okamoto Yoshitaka
Global Medical Affairs, GSK, Mumbai, Maharashtra, India.
Respiratory and Allergy, GSK, Mumbai, Maharashtra, India.
J Asthma Allergy. 2022 Nov 14;15:1645-1664. doi: 10.2147/JAA.S382441. eCollection 2022.
Our study compared knowledge of, and attitudes towards, allergic rhinitis (AR) among patients and physicians in: Brazil, Japan, Korea, Mexico, Saudi Arabia, Spain, United Arab Emirates, and the United Kingdom.
Patients with AR were recruited via probability-based sampling. Data were captured via telephone interview, personal interview, or self-administered online survey. Physicians were recruited from an online physician panel and interviewed by self-administered online survey.
In total, 1436 patients and 1637 physicians were surveyed. Most patients (76.9%) reported moderate-to-severe AR, whereas physicians reported more mild (mean cases ranging from 57.0-68.2) than moderate-to-severe AR (mean cases ranging from 31.8-43.0). Overall, most physicians (85.4%) and patients (77.5%) agreed AR could be controlled with treatment. Physicians preferred prescribing oral antihistamines (OAHs) for mild AR (from 45.3% of physicians in Brazil to 73.6% of physicians in Mexico). For moderate and severe AR, more physicians preferred prescribing intranasal corticosteroids (INCSs) and OAHs for moderate and severe AR than other available treatments (from 48.5% of physicians in the UK to 69.5% of physicians in Spain). Patients preferred OAHs to INCSs for treating AR (62.0%). Patients also reported a range of comorbidities: overall, sinus infections were the most common (24.7%), and comorbid asthma was present in 12.9% of patients. Per country, Saudi Arabia had the highest proportion (53.5%) and Mexico had the lowest proportion (8.0%) of patients with comorbid asthma.
Patient and physician perceptions of AR mostly differed between and within countries, although there was generally agreement that AR could be controlled with treatment. Differing attitudes towards AR among patients and physicians suggests a need for improved education in and communication between these groups, with subsequent implications for optimizing disease management.
我们的研究比较了巴西、日本、韩国、墨西哥、沙特阿拉伯、西班牙、阿联酋和英国的患者与医生对变应性鼻炎（AR）的了解程度和态度。
通过基于概率的抽样招募AR患者。通过电话访谈、个人访谈或自行填写的在线调查收集数据。从在线医生小组中招募医生，并通过自行填写的在线调查进行访谈。
总共对1436名患者和1637名医生进行了调查。大多数患者（76.9%）报告患有中度至重度AR，而医生报告的轻度AR（平均病例数在57.0 - 68.2之间）多于中度至重度AR（平均病例数在31.8 - 43.0之间）。总体而言，大多数医生（85.4%）和患者（77.5%）一致认为AR可以通过治疗得到控制。医生更倾向于为轻度AR开具口服抗组胺药（OAHs）（从巴西45.3%的医生到墨西哥73.6%的医生）。对于中度和重度AR，与其他可用治疗方法相比，更多医生更倾向于为中度和重度AR开具鼻内皮质类固醇（INCSs）和OAHs（从英国48.5%的医生到西班牙69.5%的医生）。患者在治疗AR时更喜欢OAHs而非INCSs（62.0%）。患者还报告了一系列合并症：总体而言，鼻窦感染最为常见（24.7%），12.9%的患者合并哮喘。按国家划分，沙特阿拉伯合并哮喘的患者比例最高（53.5%），墨西哥最低（8.0%）。
尽管普遍认为AR可以通过治疗得到控制，但患者和医生对AR的认知在不同国家之间以及国家内部大多存在差异。患者和医生对AR的态度不同表明需要改善这些群体之间的教育和沟通，这对优化疾病管理具有后续影响。
